force group was to estimate the potential costs of treatment of side effects, which theoretically may occur as a result of selected diseases treatment. The Drug Programs selected for the first part of the project were related to immune diseases, like rheumatoid arthritis, psoriasis and juvenile idiopathic arthritis. This paper aims to present the potential costs incurred by the public payer and the patients in relation to pulmonology related events.
INTRODUCTION
The project was performed within the Polish Society for Pharmacoeconomics (PTFE) Task Force group interested especially in the Drug Programs. Currently in Poland in order to ensure access to medicines, it is mandatory to perform an HTA analysis for each reimbursement dossier submission [6, 8] . Part of the HTA is related to cost-effectiveness or cost-utility analysis. Such pharmacoeconomical analysis should be done from the public payer perspective and take into account all potential direct costs [1] . The objective of the project performed by the PTFE task
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arthritis, psoriasis and juvenile idiopathic arthritis. In the analysis, it is not important which specific medicinal product was the cause of adverse event. The important issue we focused our efforts on was the treatment patterns to cure patient from the experienced adverse event. We based the adverse events selection on the Summary of Product Characteristics of the chosen products. We extracted all the potential adverse events defined as frequent and very frequent, grouping them according to therapeutic areas. Due to a large number of affected therapeutic areas in this paper we decided to present the results related to the pulmonology area. The events described as very common had an incidence of ≥ 1/10, and the common ones ≥ 1/100, <1/10 [7] . Initially, the Internet was searched in attempt to identify published treatment standards in Poland. Unfortunately, we were not able to identify such specific Polish standards.
In the next step in order to identify the resources used, a survey was performed with the engagement of clinical experts. The survey was based on an excel questionnaire sent to the clinical experts. The questions were related to the standard treatment patterns in their experts practice in case of a patient suffering from the analyzed adverse event. It included medicinal products and all other resources used, like diagnostic procedures, specialist ambulatory visits, hospitalization. With regard to the products, questions on the doses, formulation used, and time of treatment were asked. With regard to other resources used like diagnostic test, ambulatory visits, we collected information about the frequency and for hospitalization about the time of hospitalization.
The provided information was discussed with the experts and all the questions were clarified at the data collection phase. We compared all 4 pulmonology experts' opinions in order to ensure proper understanding and alignment between experts. As the next step, on the basis of the collected data, we allocated direct costs incurred by the public payer. We used the data about costs incurred by the public payer valid in December 2013.
The costs of the resources identified in the questionnaires were allocated taking into account the public payer perspective and the payer perspective including public payer and patient's spending on the adverse event treatment.
The hospitalization costs, diagnostic tests and ambulatory visits were based on the NHF costs published in 2013. For the medicinal products listed in the reimbursement list and acquired by the patient in open pharmacies, the cost incurred by public payer was also included in the analysis. When the experts indicated ambulatory treatment or an additional treatment was required after hospitalization for the broader perspective analysis, the costs incurred by the patient were calculated.
RESULTS
The aim of the project was to investigate what is the standard practice of clinicians when treating different adverse events, which were identified as hypothetical based on the Product SPCs. It was not our intention to assess safety or efficacy of treatments and we did not focus the analysis on relationship between the adverse event and the product used within the Drug Program. Our objective was to allocate costs to the resources we identified when performing the research with the use of a special questionnaire addressed to physicians. In our analysis we used the NHF costs published in December 2013 and the drug reimbursement costs incurred by public payer based on the data published by Minister of Health on 25 th October 2013. The same source was used to calculate patients' co-payment [5] .
If the doctor prescribed a medicinal product that was not reimbursed, we used for the analysis the cost of the pharmaceuticals wholesalers' price lists specified for December 2013.
The clinical experts provided names of the products used, the brand and international name.
If the most frequently used brand name was not indicated, then we included into calculations the less and the most expensive products available on the Polish market at the time of the analysis. Due to that reason, we presented the results as range of values, with a maximum and minimum value. The analysis is based on direct medical costs calculation, including the usage of resources like pharmacotherapy, diagnostics, nursing care, ambulatory visits to doctors and hospitalizations. In the case in which the experts indicated that the same adverse event could be treated in both ambulatory and hospital setting, we presented the results for both scenarios, with and without hospitalization and the hospitalization cost was calculated based on the scoring system used by NHF in the last quarter of 2013 [10] .
All the results are presented in tables and the Table 1 shows all the costs components included in the analysis. We present the direct costs incurred by public payer and by patients and the minimum and maximum values for the treatment costs as well. The presentation of costs as a percentage of the total cost of the adverse event treatment is shown in the Table 2 . Table 3 presents the detailed costs of pharmacotherapy incurred by public payer and by the patient in the ambulatory setting.
Based on the analysis results it can be observed that the highest cost for the public payer was related to the hospital treatment of the adverse events (Table 1) . Those events related to pulmonary infections, as interstitial pneumonia, interstitial alveolitis or typical mycobacterial infections generated the highest cost for the payer, as maximum the calculated value was 4184.69 PLN, 3931.30 PLN and 3415.56 PLN respectively. Asthma exacerbation treatment within the hospital ward could lead to a cost of even 2059.54 PLN from the public payer perspective. A remarkable observation concerns the patients who incurred significant costs due to the pulmonary adverse events treatment. The highest cost calculated was in case of mycotic infections (70922.13 PLN) and atypical mycobacterial infections, including tuberculosis (maximum cost 1581.60 PLN in case of hospitalization need).
The lowest cost from the public payer perspective was incurred due to runny nose and cough (29.75 PLN per episode of treatment). For the patient the minimum cost was related to those cases where the prescribed medicines were acquired in open pharmacy and reimbursed with a patient co-payment of 3.20 PLN as a lump sum, like for sinusitis treatment, bronchitis or other respiratory tract infections without hospitalization need. The percentage of different cost components is presented in the Table 2 and in most of the cases only pharmacotherapy and ambulatory visits or hospitalization were the components included in the analysis as those provided by the experts.
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Diagnostic costs were only included in case of allergic pneumonia with additional bronchial obturation or paroxysmal dry cough (30.1-62.8% of total cost was allocated to diagnostic procedures) and diagnosis of symptoms possibly related to interstitial pneumonia (0.4-0.5% of total treatment cost of this adverse event).
Pharmacotherapy was the most important cost component from the public payer perspective, from minimum contribution of 8.8% in case of asthma exacerbation episode, in some cases a maximum of 75.3%, to even the maximum contribution of 96.2-99.9% in case of the mycotic infections.
However in case of hospitalization, the pharmacotherapy costs contribution to total treatment cost was much lower in comparison to the cost generated by the hospitalization episode. The hospitalization cost was related to the length of hospitalization and can reach 94.3-97.1% of the total costs in case of interstitial alveolitis or pneumonia.
According to the experts, nursing procedures were required only in case of asthma exacerbation and equaled to 1.1-14.2% of total costs of the mentioned adverse event.
When analyzing the costs incurred during treatment in the ambulatory setting from public payer perspective and patient perspective separately significant cost in both cases were generated by chronic (allergic) pneumonia treatment, 110.04-190.96 PLN, 113.08-224.94 PLN respectively.
Another costly treatment for both the public payer and the patient was protozoal infections therapy, equal to 176.12 PLN and 176.29 PLN respectively.
The highest cost for the patient was due to mycotic infections treatment, with a cost range between 1167.12 PLN-72000 PLN. This high cost for the patient is due to potential need to use not reimbursed medicinal products. Atypical mycobacterial infections, including tuberculosis could generate a maximum cost of 1581.60 PLN for the patient.
Analyzing only the pharmacotherapy costs (Table 3) we can observe that NHF had no costs in relation to runny nose and cough. The most expensive adverse events treatment for the NHF were atypical mycobacterial infections, including tuberculosis -506.83-1563.56 PLN and mycotic infections treatment -up to 1167.12 PLN.
DISCUSSION
Our analysis presents the level of the adverse drug reactions treatment cost in the light of the experts' opinion in respiratory diseases area. In the available literature, there are no Polish publications on the cost of adverse drug reactions. In the databases we analyzed we could find some publications from other countries. Those analyses are based on retrospective data, and performed following a different methodology. The only Polish work on the cost of side effects is the work of N. Wiśniewska. N.Wiśniewska calculates the costs of adverse reactions treatment in a sample size of patients hospitalized in the Clinic of Dermatology at the Military Medical Institute in Warsaw in the years 2002-2012 [9] . Using a different methodology N. Wiśniewska presented the average cost of hospitalization of patients with drug induced skin reactions in the dermatology clinic as amounted to 2834.95 PLN. It was a lower cost in comparison to the data available from other countries. The average cost of treating adverse events in Spain in 2013 on the basis of retrospective data in hospitals was estimated at the level of 5260 EUR [2] , in France -at a range between 1300 EUR -3244 EUR [3] and in India at 5556 EUR [4] .
In this paper, we present the data related to pulmonology and we should pay particular attention to fungal infections of the upper respiratory tract, which generate very high cost for the patient. One of the interviewed experts mentioned that in opportunistic infections voriconazole is used in the treatment lasting from a few to several months. Currently available on the Polish pharmaceutical market preparations containing voriconazole are not reimbursed by the National Health Fund and therefore the cost to the patients is so high.
Referring to the available in the databases pharmacoepidemiological research related to the adverse events of medicinal products and the amount of generated costs we should consider not only the safety aspect of therapy but also be conscious of the economic impact. Current Issues in Pharmacy and Medical Sciences
CONCLUSIONS
Based on the analyzed data we can observe a significant patient contribution to the adverse events treatment cost in relation to pulmonologic diseases; often patients have to pay out of their pocket for the whole pharmacotherapy prescribed for the adverse events treatment.
The costs generated by the adverse events for the public payer are high, especially in the situation when hospitalization is required.
